Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background ART-free HIV viral control remains an unmet need for people with HIV (PWH). Trosunilimab, an anti-α4β7 integrin antibody with preserved Fc functionality, is expected to induce immune responses to control viral replication, and was evaluated in a phase 1 program in healthy volunteers (HV) and PWH. Methods The double-blind, placebo (PBO) controlled phase 1…
Background TMB-365, a second-generation post-attachment bNAb binds to the second domain of CD4 and displays improved PK, antiviral activity, and breadth of coverage when compared to ibalizumab. TMB-380 (VRC07-523LS) is a bNAb that binds to the CD4 binding site of HIV Env and has potent antiviral activity and favorable safety and PK profile. Here we…
Background To date clinical trials have been underpowered to assess the preferred antiretrovirals in therapy-naïve people with advanced HIV disease (PWAH). We investigated the efficacy and safety of an integrase inhibitor (INI) versus a boosted protease inhibitor (PI) containing regimen in PWAH. Methods In this open-label, randomised, multicentre, non-inferiority trial, therapy-naive people with HIV aged…
Background Currently, optimal timing and/or number of booster COVID19 vaccinations remains unclear. We compared immunogenicity and safety of mRNA booster vaccination at different time intervals. Methods In a randomised, controlled, multicentre, phase II trial, adults with >3 prior mRNA COVID19 vaccines, with last vaccine 3 to 7 months (M) prior, were randomized to one of…
Background Treatment with long-acting antiretroviral therapy (LA ART) with cabotegravir/rilpivirine (CAB/RPV) +/- lenacapavir (LEN) holds promise to achieve viral suppression (VS) in people with HIV (PWH) for whom oral ART fails. Although supported in certain scenarios by guidelines, scaling this approach in viremic PWH has lagged Methods We performed a retrospective review of PWH cared for…
Background The effect of metformin on reducing symptom duration among low-risk, outpatient adults with mild to moderate coronavirus disease 2019 (COVID-19) has not been studied. Our objective was to test metformin compared to placebo for symptom resolution during acute infection with SARS-CoV-2. Methods The ACTIV-6 platform clinical trial evaluated repurposed medications for mild to moderate…
Background TRAILBLAZER is a multi-center blinded, randomized trial of infusion of autologous zinc-finger endonuclease-modified CCR5-edited CD4+ lymphocytes (MC) compared to autologous infusion of unmodified CD4+ lymphocytes (UC). We hypothesized that abrogating CCR5 expression in CD4+ memory T cells would result in accelerated clearance of the replication competent HIV reservoir. Methods We enrolled PWH age 18-70…
Background In the absence of a reliable biomarker for HIV cure/remission, analytical treatment interruptions(ATIs) provide the only means for evaluating cure/remission interventions. Children who acquire HIV in utero are hypothesised to have higher cure potential due to immune ontogeny that restricts the ability of HIV to establish a large latent reservoir in the setting of…
Background Since 2022, the global population has experienced an unusual outbreak of mpox, characterized by the distinctive epidemiology of heavy-tailed sexual network partnerships within specific populations. These epidemiological characteristics resulted in an initial rapid outbreak driven by exclusive human-to-human transmission within specific populations, which facilitated a broader range of viral evolution than initially anticipated. Methods…
Background Five persons have been reported to achieve long-term HIV remission through CCR5∆32/∆32 allogeneic stem cell transplantation (SCT). Dynamics of HIV elimination after SCT are uncertain, and there are no data regarding timing of analytic treatment interruption (ATI) post SCT. Here we report sustained HIV remission despite HIV reactivation following CCR5∆32/∆32 SCT. Methods The HEME-17…